Bonnie W Lau

Prof. Dr. Bonnie W Lau

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
EFElissa Furutani
Elissa Furutani
SLShanshan Liu
Shanshan Liu
AGAshley Galvin
Ashley Galvin
SSSarah Steltz
Sarah Steltz
MMMaggie M. Malsch
Maggie M. Malsch
ASAkiko Shimamura
Akiko Shimamura
Shwachman-Diamond syndrome (SDS) is an inherited bone marrow failure syndrome with leukemia predisposition. An understanding of the hematologic complications of SDS with age could guide clinical management, but data are limited for this rare disease. We conducted a cohort study of 153 subjects from 143 families with confirmed biallelic SBDS mutations enrolled on the North American Shwachman Diamond Registry or Bone Marrow Failure Registry. The SBDS c.258 + 2T>C variant was present in all but 1 patient. To evaluate the association between blood counts and age, 2146 blood counts were analyzed for 119 subjects. Absolute neutrophil counts were positively associated with age (P < .0001). Hemoglobin was also positively associated with age up to 18 years (P < .0001), but the association was negative thereafter (P = .0079). Platelet counts and marrow cellularity were negatively associated with age (P < .0001). Marrow cellularity did not correlate with blood counts. Severe marrow failure necessitating transplant developed in 8 subjects at a median age of 1.7 years (range, 0.4-39.5), with 7 of 8 requiring transplant prior to age 8 years. Twenty-six subjects (17%) developed a myeloid malignancy (16 myelodysplasia and 10 acute myeloid leukemia) at a median age of 12.3 years (range, 0.5-45.0) and 28.4 years (range, 14.4-47.3), respectively. A lymphoid malignancy developed in 1 patient at the age of 16.9 years. Hematologic complications were the major cause of mortality (17/20 deaths; 85%). These data inform surveillance of hematologic complications in SDS.

3 August 2021 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
KSKristin A. Shimano
Kristin A. Shimano
ANAnupama Narla
Anupama Narla
MRMelissa J. Rose
Melissa J. Rose
NGNicholas J. Gloude
Nicholas J. Gloude
SASteven W. Allen
Steven W. Allen
JBJessica Boklan
Jessica Boklan

16 May 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
KSKristin A. Shimano
Kristin A. Shimano
JRJennifer A. Rothman
Jennifer A. Rothman
SASteven W. Allen
Steven W. Allen
PCPaul Castillo
Paul Castillo
JJJill L. O. de Jong
Jill L. O. de Jong
JBJessica Boklan
Jessica Boklan
Severe aplastic anemia (SAA) is a rare potentially fatal hematologic disorder. Although overall outcomes with treatment are excellent, there are variations in management approach, including differences in treatment between adult and pediatric patients. Certain aspects of treatment are under active investigation in clinical trials. Because of the rarity of the disease, some pediatric hematologists may have relatively limited experience with the complex management of SAA. The following recommendations reflect an up‐to‐date evidence‐based approach to the treatment of children with newly diagnosed SAA.

11 August 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
TNTaizo A. Nakano
Taizo A. Nakano
BLBonnie W Lau
Bonnie W Lau
KDKathryn E. Dickerson
Kathryn E. Dickerson
MWMarcin Wlodarski
Marcin Wlodarski
JPJessica Pollard
Jessica Pollard
TOTimothy S. Olson
Timothy S. Olson

22 May 2025 in Blood
Verified
Journal Article
Closed access
HRHelen D. Reed
Helen D. Reed
HDHyunwoo Do
Hyunwoo Do
EWEdie Weller
Edie Weller
MHMarian H. Harris
Marian H. Harris
CRChristopher R. Reilly
Christopher R. Reilly
ASAkiko Shimamura
Akiko Shimamura
This study identified an increased risk of lymphoid malignancy in Shwachman-Diamond syndrome (SDS) with an observed risk 38-fold higher than expected based on population data. Increased toxicity was observed with standard therapies in patients with SDS.

19 May 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
KSKristin A. Shimano
Kristin A. Shimano
GSGhadir Sasa
Ghadir Sasa
LBLarisa Broglie
Larisa Broglie
NGNicholas J. Gloude
Nicholas J. Gloude
KMKasiani Myers
Kasiani Myers
JBJessica Boklan
Jessica Boklan
Severe aplastic anemia (SAA) is a rare potentially fatal hematologic disorder. Although overall outcomes with treatment are excellent, there are variations in management approach, including differences in treatment between adult and pediatric patients. Certain aspects of treatment are under active investigation in clinical trials. Because of the rarity of the disease, some pediatric hematologists may have relatively limited experience with the complex management of SAA. The following recommendations reflect an up‐to‐date evidence‐based approach to the treatment of children with relapsed or refractory SAA.